Wissenschaftliche Arbeiten

Doç. Dr. Seval Ay Ersoy

50 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16037-8 PMID 41987096 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  4. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  5. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  6. Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020553 PMID 41598493 Frei zugänglicher VolltextQuelle: OpenAlex

  7. Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2− Metastatic Breast Cancer: A Real-World Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041671 PMID 41753358 Frei zugänglicher VolltextQuelle: OpenAlex

  8. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Quelle: OpenAlex

  9. Neoadjuvant Pertuzumab in Breast Cancer and Associated Prognostic Factors

    European Archives of Medical Research, 2026

    DOI 10.14744/eamr.2025.35682 Frei zugänglicher VolltextQuelle: OpenAlex

  10. Maintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-61625-0 PMID 42457832 Frei zugänglicher VolltextQuelle: OpenAlex

  11. Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

    Lung Cancer, 2026

    DOI 10.1016/j.lungcan.2026.109590 PMID 42664544 Frei zugänglicher VolltextQuelle: ORCID

  12. Hormon Pozitif Her2 Negatif Meme Kanserinde Neoadjuvan ve Adjuvan Tedavi Seçenekleri

    Atlas Universitesi Tip ve Saglik Bilimleri Dergisi, 2026

    DOI 10.54270/atljm.2026.117 Frei zugänglicher VolltextQuelle: ORCID

  13. Prognostic Impact of Immune-Related Adverse Events in Patients with Non–Small Cell Lung Cancer Treated with Second-Line Nivolumab: A Single-Center Real-World Experience

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.263046 Quelle: OpenAlex

  14. Treatment Outcomes and Toxicity of Cisplatin–Etoposide-Based Regimens and Carboplatin–Paclitaxel as Adjuvant Chemotherapy for Ovarian Adult Granulosa Cell Tumors: A Multicenter Retrospective Cohort Study

    Cancers, 2026

    DOI 10.3390/cancers18182910 PMID 42794877 Frei zugänglicher VolltextQuelle: OpenAlex

  15. The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer

    Medicina, 2025

    DOI 10.3390/medicina61061075 PMID 40572762 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  16. Impact of Blood Type on Treatment Response and Survival in HER2-Negative Metastatic Gastric Cancer

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25042 Frei zugänglicher VolltextQuelle: OpenAlex

  17. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  18. The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

    Medicina, 2025

    DOI 10.3390/medicina61101813 PMID 41155800 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  19. Prognostic Impact of Tumor Size in Patients with Stage T3N1 Colon Cancer

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm15010247 PMID 41517497 Frei zugänglicher VolltextQuelle: OpenAlex

  20. Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

    Medicina, 2025

    DOI 10.3390/medicina61050819 PMID 40428777 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  21. Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-1-1 Frei zugänglicher VolltextQuelle: OpenAlex

  22. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-29276-9 PMID 41315659 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  23. Prognostic impact of pan-immune-inflammation value and prognostic nutritional index in metastatic colorectal cancer patients treated with regorafenib

    The European Research Journal, 2025

    DOI 10.18621/eurj.1768888 Frei zugänglicher VolltextQuelle: ORCID

  24. Prognostic factors and the impact of adjuvant chemotherapy on recurrence and survival in stage I non-small cell lung cancer: A real-world study

    The European Research Journal, 2025

    DOI 10.18621/eurj.1633305 Frei zugänglicher VolltextQuelle: ORCID

  25. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 Zitation (Europe PMC) Quelle: OpenAlex

  26. Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens

    Oncology Letters, 2023

    DOI 10.3892/ol.2023.13795 PMID 37123028 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  27. The Predictive Importance of Body Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

    Breast Care, 2023

    DOI 10.1159/000526732 PMID 36876171 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  28. Combining Immunotherapy with Transarterial Radioembolization.

    Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India, 2023

    DOI 10.4103/ijnm.ijnm_180_22 PMID 37456187 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  29. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

    Expert Review of Anticancer Therapy, 2022

    DOI 10.1080/14737140.2022.2076670 PMID 35543015 3 Zitationen (Europe PMC) Quelle: OpenAlex

  30. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2040770 PMID 35174772 Frei zugänglicher VolltextQuelle: OpenAlex

  31. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2026125 PMID 35037592 15 Zitationen (Europe PMC) Quelle: OpenAlex

  32. ¿Es el intervalo libre de docetaxel un factor predictivo para el cáncer de próstata resistente a la castración?

    Actas Urológicas Españolas, 2022

    DOI 10.1016/j.acuro.2021.10.003 Quelle: ORCID

  33. Is adipose tissue metabolic activity a predictor of pathological responses to neoadjuvant treatment in breast cancer

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2022

    DOI 10.1016/j.remnie.2022.08.003 PMID 35988844 4 Zitationen (OpenAlex) Quelle: OpenAlex

  34. Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?

    Actas Urológicas Españolas (English Edition), 2022

    DOI 10.1016/j.acuroe.2021.10.005 PMID 35786543 Quelle: OpenAlex

  35. ¿Es la actividad metabólica del tejido adiposo un predictor de respuesta histopatológica al tratamiento neoadyuvante en el cáncer de mama?

    Revista Española de Medicina Nuclear e Imagen Molecular, 2022

    DOI 10.1016/j.remn.2022.05.002 Quelle: OpenAlex

  36. Second Line Treatment Choice in Extensive Small Lung Cancer

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2022.72208 Quelle: OpenAlex

  37. Alveolar Soft Part Sarkomlar ve Periferik Sinir Kılıfı Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.2239.c17320 Quelle: OpenAlex

  38. Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0398 PMID 34323116 2 Zitationen (Europe PMC) Quelle: OpenAlex

  39. Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

    European Journal of Breast Health, 2021

    DOI 10.4274/ejbh.galenos.2020.6346 PMID 33870111 11 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  40. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220924088 PMID 32423326 8 Zitationen (Europe PMC) Quelle: ORCID

  41. Onkolojide Destek Tedaviler ve Semptom Yönetimi

    Akademisyen Kitabevi eBooks, 2021

    DOI 10.37609/akya.180 Quelle: OpenAlex

  42. The role of mean platelet volume in nonalcoholic fatty liver disease without cardiovascular comorbidities, obesity and diabetes mellitus

    European Journal of Gastroenterology & Hepatology, 2021

    DOI 10.1097/meg.0000000000002189 PMID 34397640 2 Zitationen (Europe PMC) Quelle: ORCID

  43. Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220951612 PMID 32847482 2 Zitationen (Europe PMC) Quelle: ORCID

  44. Role of tumor location on high-grade serous ovarian cancer prognosis.

    Ginekologia polska, 2021

    DOI 10.5603/gp.a2021.0123 PMID 34105739 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  45. Initial Ca 125 Value as a Predictive Marker for High-grade Serous Ovarian Cancer

    Journal of the College of Physicians and Surgeons Pakistan, 2021

    DOI 10.29271/jcpsp.2021.06.651 PMID 34102775 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  46. Evaluation of pharmacist interventions and commonly used medications in the geriatric ward of a teaching hospital in Turkey: a retrospective study

    Clinical Interventions in Aging, 2019

    DOI 10.2147/cia.s201039 PMID 30962679 25 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  47. Neoadjuvant treatment in patients with locally advanced gastric cancer.

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.4_suppl.127 3 Zitationen (OpenAlex) Quelle: ORCID

  48. Case report: An atypical presentation of dementia with affective disorder

    DergiPark (Istanbul University), 2019

    Quelle: OpenAlex

  49. Associations between metabolic syndrome and osteoporosis in elderly with chronic thyroiditis treated with thyroid hormone

    Clinical Nutrition, 2018

    DOI 10.1016/j.clnu.2018.06.1940 Quelle: OpenAlex

  50. Kronik böbrek hastalarında intravenöz demir tedavisi, oksidatif stres ve N-asetilsistein'in etkisi

    Turkish Journal of Nephrology, 2011

    Quelle: OpenAlex